Literature DB >> 24141004

Outcomes of screening endometrial cancer patients for Lynch syndrome by patient-administered checklist.

Molly S Daniels1, Diana L Urbauer, Azadeh Zangeneh, Brittany A L Batte, Katherine M Dempsey, Karen H Lu.   

Abstract

OBJECTIVE: The aims of this study were to implement a patient-administered checklist designed to identify endometrial cancer patients at elevated risk for Lynch syndrome; measure subsequent genetic counseling and testing; and identify differences between those who attended genetic counseling and those who did not.
METHODS: We developed a 4-item yes/no checklist of personal and family history risk factors for Lynch syndrome-associated endometrial cancer and recommended referral for genetic counseling for patients meeting any of the criteria. Retrospective chart review was performed to determine subsequent genetic counseling and testing outcomes over a 15 month period.
RESULTS: 6/387 (1.6%) of endometrial cancer patients tested positive for a Lynch syndrome mutation. 4/24 (17%) of endometrial cancer patients who met referral criteria and attended genetic counseling tested positive. 38/70 (55%) of patients who met referral criteria were not seen for genetic counseling. Patients who were diagnosed with endometrial cancer at younger ages, who had primary surgery at our institution, or who met more than one referral criteria were more likely to be seen for genetic counseling.
CONCLUSIONS: Endometrial cancer patients who met referral criteria and attended genetic counseling comprised a population enriched for Lynch syndrome. This approach allowed Lynch syndrome evaluation resources to be targeted to a population of patients that is high risk and interested in the information. The referral rate of at-risk patients needs to be improved, and allocating resources towards this goal could increase the identification of Lynch syndrome while avoiding some of the pitfalls of universal screening.
© 2013.

Entities:  

Keywords:  Endometrial cancer; Genetic counseling; Genetic testing; Lynch syndrome

Mesh:

Year:  2013        PMID: 24141004      PMCID: PMC4123330          DOI: 10.1016/j.ygyno.2013.10.011

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  29 in total

1.  Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer ≤ 70 years.

Authors:  Celine H M Leenen; Margot G F van Lier; Helena C van Doorn; Monique E van Leerdam; Sjarlot G Kooi; Judith de Waard; Robert F Hoedemaeker; Ans M W van den Ouweland; Sanne M Hulspas; Hendrikus J Dubbink; Ernst J Kuipers; Anja Wagner; Winand N M Dinjens; Ewout W Steyerberg
Journal:  Gynecol Oncol       Date:  2012-02-01       Impact factor: 5.482

2.  Endometrial cancer patients and compliance with genetic counseling: room for improvement.

Authors:  Floor J Backes; Elizabeth Mitchell; Heather Hampel; David E Cohn
Journal:  Gynecol Oncol       Date:  2011-10-02       Impact factor: 5.482

3.  Testing women with endometrial cancer to detect Lynch syndrome.

Authors:  Janice S Kwon; Jenna L Scott; C Blake Gilks; Molly S Daniels; Charlotte C Sun; Karen H Lu
Journal:  J Clin Oncol       Date:  2011-05-02       Impact factor: 44.544

4.  Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer.

Authors:  Shiyu Zhang; Robert Royer; Song Li; John R McLaughlin; Barry Rosen; Harvey A Risch; Isabel Fan; Linda Bradley; Patricia A Shaw; Steven A Narod
Journal:  Gynecol Oncol       Date:  2011-02-15       Impact factor: 5.482

Review 5.  Application of molecular techniques in the diagnosis, prognosis and management of patients with colorectal cancer: a practical approach.

Authors:  Mark P Legolvan; Ross J Taliano; Murray B Resnick
Journal:  Hum Pathol       Date:  2012-06-01       Impact factor: 3.466

6.  Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results.

Authors:  Laura C Beamer; Marcia L Grant; Carin R Espenschied; Kathleen R Blazer; Heather L Hampel; Jeffrey N Weitzel; Deborah J MacDonald
Journal:  J Clin Oncol       Date:  2012-02-21       Impact factor: 44.544

Review 7.  DNA mismatch repair deficiency in endometrial carcinoma.

Authors:  Yevgeniy Karamurzin; Joanne K L Rutgers
Journal:  Int J Gynecol Pathol       Date:  2009-05       Impact factor: 2.762

8.  Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives.

Authors: 
Journal:  Genet Med       Date:  2009-01       Impact factor: 8.822

9.  Integrated genomic analyses of ovarian carcinoma.

Authors: 
Journal:  Nature       Date:  2011-06-29       Impact factor: 49.962

10.  The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer.

Authors:  Mercy Mvundura; Scott D Grosse; Heather Hampel; Glenn E Palomaki
Journal:  Genet Med       Date:  2010-02       Impact factor: 8.822

View more
  3 in total

1.  Consequences of universal MSI/IHC in screening ENDOMETRIAL cancer patients for Lynch syndrome.

Authors:  Brittany A L Batte; Amanda S Bruegl; Molly S Daniels; Kari L Ring; Katherine M Dempsey; Bojana Djordjevic; Rajyalakshmi Luthra; Bryan M Fellman; Karen H Lu; Russell R Broaddus
Journal:  Gynecol Oncol       Date:  2014-06-14       Impact factor: 5.482

2.  Evaluating the impact of universal Lynch syndrome screening in a publicly funded healthcare system.

Authors:  Petra W C Lee; Angela C Bedard; Setareh Samimi; Vivienne K Beard; Quan Hong; James E J Bedard; Blake Gilks; David F Schaeffer; Robert Wolber; Janice S Kwon; Howard J Lim; Sophie Sun; Kasmintan A Schrader
Journal:  Cancer Med       Date:  2020-07-23       Impact factor: 4.452

Review 3.  Colorectal Cancer Screening and Surveillance for Non-Hereditary High-Risk Groups-Is It Time for a Re-Think?

Authors:  James S Hampton; Linda Sharp; Dawn Craig; Colin J Rees
Journal:  Curr Treat Options Gastroenterol       Date:  2021-01-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.